Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
Nuvation Bio has entered into an exclusive licensing agreement with Eisai for taletrectinib, an advanced oral treatment for ROS1-positive non-small cell lung cancer. This partnership grants Eisai development, registration, and commercialization rights in Europe and several other countries, excluding the U.S., China, and Japan where the drug is already approved. Nuvation Bio will receive an upfront payment of €50 million, up to €145 million in milestone payments, and tiered royalties from sales in the licensed territories.
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Eisai and Nuvation Bio have formed an exclusive licensing agreement for taletrectinib, an advanced ROS1-positive non-small cell lung cancer treatment, covering Europe and several other global territories. Under the agreement, Nuvation Bio will receive an upfront payment of EUR 50 million, up to EUR 145 million in milestone payments, and double-digit tiered royalties on sales. This partnership aims to expand the availability of taletrectinib, which is already approved in the U.S., China, and Japan, to a broader international patient population.
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
Nuvation Bio and Eisai have announced an exclusive licensing agreement for taletrectinib, a treatment for ROS1-positive non-small cell lung cancer, in Europe and other regions outside the U.S., China, and Japan. Nuvation Bio will receive an upfront payment of €50 million, up to €145 million in milestone payments, and double-digit tiered royalties on sales. This collaboration aims to expand the global reach of taletrectinib, which is already approved in the U.S., China, and Japan.
Nuvation Bio Inc.'s (NYSE:NUVB) institutional investors lost 5.2% last week but have benefitted from longer-term gains
Institutional investors, holding 57% of Nuvation Bio Inc. (NYSE:NUVB), experienced a 5.2% loss last week, though a 182% one-year return has mitigated some impact. The company's top five shareholders control 52% of the business, with CEO David Hung being the largest individual shareholder at 18%, and insiders collectively owning 25% of the company. Alongside retail investors and private equity firms, these groups significantly influence the company's share price and strategic decisions.
Nuvation Bio’s chief medical officer sells $1.17 million in stock
Dongfang Liu, the Chief Medical Officer of Nuvation Bio Inc. (NASDAQ:NUVB), sold 150,000 shares of Class A Common Stock for $1.17 million at a weighted-average price of $7.8217. Concurrently, Liu exercised options to acquire 150,000 shares at $2.93 each, highlighting a significant gain from the company's strong performance, with the stock up 204.9% in six months. Following these transactions, Liu directly holds 18,000 shares, and the company has a market capitalization of $2.85 billion.
Nuvation Bio officer Liu sells $155k in shares
Nuvation Bio Chief Medical Officer Dongfang Liu sold 20,000 shares of Class A Common Stock for $155,000, while also exercising options to acquire an equal number of shares for $72,200. This follows a strong third-quarter earnings report for Nuvation Bio, which surpassed revenue expectations and saw positive analyst coverage and increased price targets due to the successful commercial launch of its lead drug, Ibtrozi. These developments reflect growing confidence in Nuvation Bio's market position and future prospects.
Nuvation Bio officer Liu sells $155k in shares
Nuvation Bio's Chief Medical Officer, Dongfang Liu, sold 20,000 shares of Class A Common Stock for $155,000 across November 25-26, 2025, while also exercising options to acquire 20,000 shares for $72,200. This follows Nuvation Bio's strong third-quarter 2025 earnings, which significantly surpassed revenue expectations and led to positive analyst coverage with "Buy" ratings and increased price targets. The company's lead drug, Ibtrozi, and promising results from safusidenib contributed to growing investor confidence.
Nuvation Bio (NUVB) Jumps to 3-Year High on Bullish Coverage
Nuvation Bio (NUVB) saw its stock price jump to a three-year high following positive analyst coverage. Investors reacted favorably to the bullish sentiment, pushing the stock upward. This surge indicates renewed confidence in the company's prospects among market participants.
Nuvation Bio (NUVB) Stock Soars ~50% Today as B. Riley Starts Coverage With $12 Target – 19 November 2025
Nuvation Bio (NUVB) stock surged approximately 50% after B. Riley Securities initiated coverage with a "Buy" rating and a $12 price target, driven by the successful launch of its lung cancer drug IBTROZI™ and strong Q3 2025 financial results. The company's leadership also presented at the Jefferies Global Healthcare Conference in London, further boosting investor interest. While the stock's valuation reflects high expectations, it is underpinned by tangible clinical data and explosive revenue growth for IBTROZI.
Nuvation Bio Inc. (NUVB) is a Buy at H.C. Wainwright on Cancer Drug Development Progress
H.C. Wainwright analyst Robert Burns reiterated a Buy rating and a $10 price target on Nuvation Bio Inc. (NUVB) after the company announced the enrollment of 204 new patients in its IBTROZI cancer therapy trial for non-small cell lung cancer. The drug shows robust durability, with a 50-month median duration of response, and the company is set to receive a $25 million milestone payment from its partner Nippon Kayaku following regulatory approval in Japan. Nuvation Bio also reported increased revenue from collaboration and licensing agreements, primarily due to its partnership with Nippon Kayaku.
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Nuvation Bio Inc. (NYSE: NUVB) announced its financial results for the third quarter ended September 30, 2025, highlighting significant progress in its clinical programs and commercialization efforts. The company successfully initiated treatment for 204 patients with IBTROZI™ (taletrectinib) and reported a median Duration of Response of 50 months for the drug in ROS1-positive NSCLC. Nuvation Bio also enrolled the first patients in key studies for safusidenib and IBTROZI, while maintaining a strong cash balance of $549.0 million.
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Nuvation Bio reported its Q3 2025 financial results, highlighting successful commercialization of IBTROZI™ with 204 new patients initiated. The company also announced an updated median Duration of Response of 50 months for IBTROZI in ROS1+ NSCLC and progression in its safusidenib and NUV-1511 clinical programs. Nuvation Bio concluded the quarter with a strong cash position of $549.0 million.
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Nuvation Bio announced its Q3 2025 financial results, highlighting the successful launch of IBTROZI™ (taletrectinib) with 204 new patients started, and an updated median Duration of Response (DOR) of 50 months for the drug in ROS1-positive NSCLC. The company also reported progress in its pipeline, including the enrollment of the first patient in a registrational study for safusidenib and the TRUST-IV phase 3 study for IBTROZI, while maintaining a strong cash position of $549.0 million.
Nuvation Bio Inc. (NYSE:NUVB) Receives $7.86 Consensus PT from Brokerages
Nuvation Bio Inc. (NYSE:NUVB) has received a consensus price target of $7.86 from brokerages, with several analysts issuing "buy" or "outperform" ratings and specific price targets. The company's stock recently dropped by 6.1%, and institutional investors hold a significant portion of its shares. Nuvation Bio is a clinical-stage biopharmaceutical company focused on oncology therapies, with lead product candidates NUV-868, NUV-1156, and a drug-drug conjugate platform, as well as NUV-1176.
Nuvation Bio’s (NUVB) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Wedbush reaffirmed its "Outperform" rating on Nuvation Bio (NUVB) in a recent report. Several other analysts have also issued positive ratings with price objectives between $6.00 and $10.00. Institutional investors have significantly increased their holdings in Nuvation Bio, with hedge funds and other institutional investors owning 61.67% of the stock.
Nuvation Bio Surges on Japanese Approval of Ibtrozi for Lung Cancer
Nuvation Bio's stock surged after receiving Japanese approval for its lung cancer drug, Ibtrozi, for ROS1-positive non-small cell lung cancer. This approval is a significant regulatory win, with a $25 million milestone payment expected. Despite financial headwinds and negative margins, analysts see uplift potential if strategic execution aligns with market developments.
Nuvation Bio Says Japan Approves IBTROZI For ROS1+ Advanced Non-small Cell Lung Cancer Treatment
Nuvation Bio Inc. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved IBTROZI (taletrectinib) for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC). This approval is part of an exclusive license agreement with Nippon Kayaku, which will commercialize IBTROZI in Japan. Nuvation Bio expects to receive a $25 million milestone payment in Q4 2025 upon the establishment of the reimbursement price in Japan.
Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
Nuvation Bio Inc. announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved IBTROZI (taletrectinib) for adult patients with advanced ROS1-positive non-small cell lung cancer. This approval follows earlier regulatory approvals in the U.S. and China, emphasizing IBTROZI's potential as a best-in-class treatment. The company expects a $25 million milestone payment upon the establishment of the reimbursement price in Japan.
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
Nuvation Bio Inc. has reported its financial results for the second quarter ended June 30, 2025, highlighting the FDA approval of IBTROZI™ (taletrectinib) for advanced ROS1-positive NSCLC and its successful commercial launch with 70 patients started on treatment. The company also provided updates on its pipeline, including safusidenib for IDH1-mutant glioma and NUV-1511 for advanced solid tumors, and detailed its strong financial position with $607.7 million in cash, cash equivalents, and marketable securities.
Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
Nuvation Bio announced it will present new data on its recently FDA-approved drug, IBTROZI™ (taletrectinib), for advanced ROS1-positive non-small cell lung cancer (NSCLC) at the IASLC 2025 World Conference on Lung Cancer (WCLC) and the European Society of Medical Oncology (ESMO) Congress. The presentations will include updated efficacy and safety results from the pivotal Phase 2 TRUST-I and TRUST-II studies, as well as preclinical and pharmacologic insights. These findings aim to reinforce IBTROZI's established profile as an important treatment option for patients with ROS1+ NSCLC.
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers
Nuvation Bio Inc. has announced that its drug, taletrectinib (IBTROZI™), has been added as a Preferred Agent in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for ROS1-positive NSCLC. This inclusion covers both first-line and subsequent therapy, specifically addressing patients with brain metastases and acquired resistance mutations. The NCCN's swift action follows the FDA approval of taletrectinib on June 11 for locally advanced or metastatic ROS1+ NSCLC, highlighting the drug's importance for this aggressive form of lung cancer.
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
The FDA has approved Nuvation Bio's IBTROZI™ (taletrectinib) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). This next-generation oral ROS1 tyrosine kinase inhibitor demonstrated high response rates, durable benefit, and intracranial activity in clinical trials. The approval offers a new treatment option for this rare and aggressive form of lung cancer, particularly for patients with brain metastases.
Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib
Nuvation Bio announced key updates for its ROS1 inhibitor, taletrectinib, including an oral presentation of TRUST-II study data at WCLC 2024 and a poster presentation of pooled TRUST-I and TRUST-II data at ESMO 2024. The pooled data will support the Company’s New Drug Application in the United States, with commercialization anticipated in 2025. Additionally, the U.S. FDA granted Orphan Drug Designation to taletrectinib for treating ROS1-positive non-small cell lung cancer and other NSCLC indications.
Nuvation Bio Appoints Colleen Sjogren as Chief Commercial Officer
Nuvation Bio Inc. (NYSE: NUVB) has appointed Colleen Sjogren as its Chief Commercial Officer, where she will lead the company's commercial strategy and operations. This appointment comes as Nuvation Bio aims to transform into a late-stage global oncology company with potential for commercial-stage operations by late 2025. Ms. Sjogren brings extensive experience in developing commercial organizations and launching successful oncology medicines.
FDA Clears IND of NUV-1511 for Advanced Solid Tumors
The FDA has cleared Nuvation Bio's investigational new drug (IND) application for NUV-1511, a novel drug candidate for advanced solid tumors. This clearance enables a phase 1/2 clinical trial to begin in the first half of 2024, expanding Nuvation Bio's clinical pipeline and validating its proprietary drug-drug conjugate (DDC) platform. NUV-1511 aims to selectively deliver potent anti-cancer therapies to tumor cells, offering potential benefits for patients with various solid tumors who have progressed on other treatments.
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
Nuvation Bio (NYSE: NUVB) has announced the discontinuation of its NUV-422 clinical development program due to safety concerns related to uveitis and feedback from the FDA. The company will now prioritize its NUV-868 program and a novel small molecule Drug-Drug Conjugate (DDC) platform. This restructuring, including a 35% workforce reduction, is expected to extend Nuvation Bio's cash runway through 2028.
